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Introduction
High rates of cellular proliferation are a key component of
aggressive breast cancers. Markers of proliferation, such
as Ki67, are widely used to identify cancers with high
proliferative indices and have the potential to alter
treatment rationale [1–3]. In addition, determining cellular
proliferation rates provides an insight into the intrinsic
biology of a tumour, indicating the degree of growth
stimulation that is contributing to increasing tumour size.
The human epidermal growth factor receptor (HER) family
of receptor tyrosine kinases forms part of a complex signal
cascade modulating cell proliferation, survival, adhesion,
migration and differentiation. The family comprises four
homologous receptors, HER1 (EGFR/ErbB1), HER2
(ErbB2/neu), HER3 (ErbB3) and HER4 (ErbB4) [4]. Over-
expression of all four receptors has been observed in
BLI = bromodeoxyuridine labelling index; BrdU = bromodeoxyuridine; ER = oestrogen receptor; HER = human epidermal growth factor receptor; Tpot
= potential tumour doubling time.
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Abstract
Background: We have shown previously that whereas
overexpression of human epidermal growth factor receptor
(HER)1, HER2 and HER3 is associated with poor prognosis in
breast cancer, HER4 is associated with a good prognosis. Cell
proliferation is a key component of aggressive cancers and is
driven by growth factors. In this study, bromodeoxyuridine
(BrdU)-derived proliferation indices are correlated with clinical
outcome and HER1–4 status for further clarification of the
differing roles for the HER family at a biological level.
Methods: Seventy-eight invasive breast cancers had BrdU
labelling in vivo to determine the BrdU labelling index (BLI) and
the potential tumour doubling time (Tpot). Long-term clinical
follow-up was available for these patients. We used
immunohistochemistry to establish the HER1–4 status in 55
patients from the BrdU cohort.
Results: We demonstrate a significant correlation between
high BLI values and breast cancer-specific death (P = 0.0174).
Low Tpot times were also significantly correlated with breast
cancer-specific death (P = 0.0258). However, BLI did not
independently predict survival in Cox’s multiple regression
analysis when combined with other prognostic factors such as
size, grade and nodal status. Tumours found to be positive for
HER1, HER2 or HER3 had significantly (P = 0.041) higher
labelling indices, with HER1 also showing significantly higher
indices when considered independently (P= 0.024). Conversely,
HER4 positivity was significantly correlated (P = 0.013) with
low BLI values, in line with previous data associating this
receptor with good prognosis tumours.
Conclusions: These results support the hypothesis that
HER1–3 are associated with driving tumour proliferation,
whereas HER4 is involved in a non-proliferative or even
protective role.
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breast cancer [5–8]. We have recently shown that patients
with overexpression of HER1–3 exhibit markedly reduced
survival, whereas patients with overexpression of HER4
demonstrate increased survival in comparison with patients
not expressing high levels of any of these receptors [9].
There is published evidence suggesting that HER4 is less
able to recruit proliferative (RAS/RAF) signal transduction
pathways than other HER family members [4,10]. We
have therefore postulated that the apparent protective
effect of HER4 might be reflected by lower proliferative
indices, while cases with a higher expression of HER1–3
would have higher proliferative indices.
HER1 and HER2 are both linked to poor prognostic
factors in breast cancer [8,11–14]. Conflicting evidence is
available on the prognostic significance of HER3: some
studies show a relationship between HER3 and some
markers of poor prognosis [9,15,16], but others have
shown that HER3 overexpression is consistent with a
good prognostic outlook [17,18]. HER4 has more
consistently been linked to good prognostic factors and a
longer disease-free interval [9,19,20]. We have therefore
studied HER1–4 expression in a cohort of patients in
whom we have previously performed BrdU labelling to
determine tumour proliferative indices and potential
tumour doubling times [21] to investigate further the
biological significance of HER1–4 overexpression with
respect to cellular proliferation.
Methods
Patients
Eighty-nine patients who had a breast cancer more than
2 cm in diameter were recruited in the original study
between 1989 and 1992. This size criterion was used to
ensure that adequate tissue was available for analysis
once diagnostic needs had been met. Only post-
menopausal patients were entered, in view of the unknown
embryotoxicity of bromodeoxyuridine (BrdU). The relevant
ethics committees gave approval. Patients who had either
breast conservation or mastectomy were included, as
were those having adjuvant radiotherapy, chemotherapy or
tamoxifen as part of protocols at that time. Follow-up
status was obtained by review of patients’ records, with
further clarification from data held by the Scottish Cancer
Intelligence Unit when there was any doubt over the cause
of death. Calculation of bromodeoxyuridine labelling index
(BLI) was possible in 84 patients. Four patients were lost
to follow-up and two patients were excluded from survival
analysis because they had metastasis at the time of
diagnosis. Two patients had bilateral tumours; in these
cases the tumour with the highest BLI value was included.
Thus there were 78 cases in whom BLI and follow-up
were available, with calculation of potential tumour
doubling time (Tpot) present for 55 of them. Material for
evaluation of HER1–4 status was available for 55 of the
labelled cases.
Labelling with BrdU
BrdU (200 mg) was administered as an intravenous bolus
4–10 hours before surgery. Tumour sample specimens
were subjected to flow cytometric analysis; the sub-
sequent calculation of BLI and Tpot values has been
described previously [21]. The BLI is presented as a
percentage of tumour cells that became labelled with
BrdU (that is, within the DNA-synthetic S phase of the cell
cycle during exposure to BrdU). The Tpot is a measure of
the minimum time to doubling of tumour size based on
calculation of the length of the S phase (Ts) and is
expressed in days.
HER1–4 status
HER1–4 status was determined in 55 patients by immuno-
histochemistry with specific antibodies, as described
previously [9]. Scoring of membrane staining was
performed with excellent agreement between observers
(inter-class correlation coefficient 0.892).
Statistics
All statistical analysis was performed with the SPSS
statistical package (version 9.0.0). Kaplan–Meier life-table
analysis was undertaken with log-rank testing of
differences in breast cancer-related survival (end-point
breast cancer-specific death). BLI values in the 75th
centile or higher were stratified as ‘high’ values, and Tpot
values in the 25th centile or lower were classified as ‘low’
values for the purpose of survival calculations. These cut-
offs were used to identify the relevant ‘high-risk’
populations with regard to their proliferation indices.
Multivariate analysis with Cox’s multiple regression
analysis was performed with the inclusion of known
prognostic values such as grade, nodal status and tumour
size. The Mann–Whitney test using mean ranks was used
to evaluate any correlation between BLI values and
HER1–4 status.
Results
Patients
The median age of patients (n = 78) included in the
analysis was 64.6 years. Median follow-up available was
6.6 years (range 0.1–13 years). There were 35 breast
cancer-specific deaths and a further 15 deaths from un-
related causes (mainly cardiac/lung disease, with 4 deaths
from other cancers). There were 69 ductal tumours, 4
lobular tumours and 5 other or non-specified types. There
were 44 oestrogen receptor (ER)-positive and 30 ER-
negative cases (4 unknown). The mean size of the
tumours is 32.1 ± 20.9 mm (mean ± SD), with a median of
27 mm (interquartile range 20–40 mm). The nodal status
was known on 74 patients; 40 had no nodal involvement,
23 had one to three nodes involved and 11 had more than
three nodes involved (Table 1). Forty-four patients received
a mastectomy, and 34 patients had a wide local excision.
For the patients with known adjuvant treatment details,Breast Cancer Research    Vol 6 No 3 Tovey et al.
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93% (69 of 74) received tamoxifen and only 4% (3 of 71)
received chemotherapy.
BLI and Tpot
The mean BLI was 4.0 ± 3.1% (mean ± SD), with the
median at 3.2% (interquartile range 1.3–6.4%). The mean
Tpot was 28.3 ± 29.3 days (mean ± SD) with the median
at 14.6 days (interquartile range 8.0–37.5 days). BLI and
Tpot are inversely related in a nonlinear fashion with a
Spearman rank correlation coefficient of –0.938 (at a 0.01
significance level). For this reason and because of the
smaller numbers in the Tpot group, regression analysis and
correlations with the HER group were performed with BLI
only.
HER1–4
HER overexpression was defined as described by Witton
and colleagues [9]; 13% (7 of 55) of patients were HER1
positive, 19% (10 of 54) were HER2 positive, 20% (10 of
51) were HER3 positive and 11% (6 of 54) were HER4
positive (Table 2). Eighteen (48%) patients were positive
for at least one of HER1, HER2 or HER3 (HER1–3 positive).
HER1 positivity was significantly correlated with increased
BLI values (P = 0.024); median BLI values for HER1-over-
expressing tumours were 2.5-fold those for HER1-negative
cases. BLI values for HER2 and HER3 positive tumours
were respectively 42% and 69% higher than for tumours
not expressing these proteins at high levels. Neither value
reached significance levels (P = 0.216 and P = 0.313).
However, when patients positive for one or more of HER1,
HER2 and HER3 (n = 18) are considered, this group had
significantly higher BLI values (P = 0.041) than patients
with tumours that did not express these proteins.
Conversely, tumours with high HER4 expression showed
BLI values significantly lower than tumours not expressing
HER4 (P = 0.013), with a median reduction in BLI of 65%.
Table 1
Tumour size, grade, nodal status and oestrogen receptor
status of cohort
Parameter n
Tumour size
T1 31
T2 39
T3 7
Unknown 1
Grade
11 4
22 6
33 6
Unknown 2
Nodal status
Negative 40
1–3 nodes 23
3+ nodes 11
Unknown 4
Oestrogen receptor status
Positive 44
Negative 30
Unknown 4
Table 2
Relationship between bromodeoxyuridine labelling index (BLI)
values and human epidermal growth factor receptor (HER)1–4
status
HER Status n Median Mean rank P
HER1 Positive 7 6.3 40.71 0.024
Negative 48 2.5 26.15
HER2 Positive 10 4.2 33.05 0.216
Negative 44 2.95 26.24
HER3 Positive 10 5.25 30.25 0.313
Negative 41 3.1 24.96
HER4 Positive 6 1.05 12.83 0.013
Negative 48 3.25 29.33
HER1–3 Positive 18 4.4 34.33 0.041
Negative 37 2.5 24.92
P values were obtained with the Mann–Whitney test.
Figure 1
Survival curves (Kaplan–Meier) for bromodeoxyuridine labelling index
(BLI). Cumulative survival differences between patients whose tumours
had high BLI values (at least 75th centile; that is, 6.4%) and low BLI
values (below 75th centile). P values represent log-rank differences in
cumulative survival between the two groups.Survival
Patients with higher BLI values (75th centile or higher;
n = 20) had a significantly poorer prognosis in terms of
survival (10-year survival 35%) from breast cancer than
patients with BLI values below the 75th centile (n = 58;
10-year survival 60%; p = 0.0174 [log-rank test]; Fig. 1).
Patients with low Tpot times (25th centile or below; n = 14)
had significantly lower survival (10-year survival 29%) than
patients with Tpot times above the 25th centile (n = 41;
10-year survival 58%; P = 0.0258 [log-rank test]; Fig. 2).
Further stratification of BLI and Tpot into other quartile
groups did not show improved distinction in terms of
survival (data not shown).
When BLI and HER status were included in Cox’s multiple
regression analysis along with known prognostic variables
(Table 3), size and HER1–3 status were the only
independent predictors of survival.
Discussion
Studies of tumour labelling index have shown significant
correlations between high proliferation indices and poor
outcome [22,23], although this is not always true in the
context of a multivariate analysis [24,25]. More recently
the proliferation marker Ki67, a nuclear antigen expressed
in the G1, S, G2 and M cell phases but not in G0 [26],
has been used as a proliferation marker. These methods
provide ‘static’ information about the cell cycle at a single
point in time but do not give any information about the rate
of progress of the cells through the cycle. Providing
dynamic information about the rate of cell cycling might be
a more accurate reflection of tumour growth because it
permits the estimation of parameters such as the potential
doubling time. With the use of flow cytometry and in vivo
labelling with the thymidine analogue BrdU it is possible to
obtain both BLI and Tpot [27,28].
We have shown that tumours with either high BLI values
or low Tpot times have significantly poorer breast cancer-
specific survival rates. However, together with other
known prognostic factors, BLI was not shown to be an
independent prognostic factor in multivariate analysis. This
might reflect the small size of the present study rather than
any failure of the method itself, because stage, grade and
ER status were also not significant indices of survival in
this study. Cutress and colleagues [29] followed up 75
patients with invasive breast cancer but did not show any
significant correlation between proliferation data and
outcome measures. A larger study of 129 patients showed
a significant correlation between low proliferation indices
and survival that persisted in multivariate analysis when
known prognostic factors such as node status, age and
size of the tumour were included [3].
Tumour growth, which we have sought to measure by
calculating Tpot, is a balance between cell growth and cell
loss and is therefore affected by factors such as
oxygenation and apoptosis. BrdU labelling does not
provide any information about cell loss, which is now
recognised to be a significant factor in determining the
actual growth of a tumour. Future measurements that
include an estimate of both proliferation and cell loss
might provide more accurate prognostic indices. The use
of molecular profiling to identify tumours with differing
proliferative and apoptotic signatures might provide
valuable information in the future [30].
Available online http://breast-cancer-research.com/content/6/3/R246
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Figure 2
Survival curves (Kaplan–Meier) for potential tumour doubling time
(Tpot). Cumulative survival differences between patients whose tumours
had low Tpot values (25th centile or less; that is, 8.0 days) or high Tpot
values (more than 25th centile). P values represent log-rank
differences in cumulative survival between the two groups.
Table 3
Results of Cox’s multivariate regression analysis for
bromodeoxyuridine labelling index (BLI), human epidermal
growth factor receptor (HER) status and known prognostic
variables
Variable (n = 48) P
Grade 0.155
Size 0.008
Nodal status 0.283
Oestrogen receptor status 0.197
BLI 0.052
HER1–3 status 0.003
HER4 status 0.985Breast Cancer Research    Vol 6 No 3 Tovey et al.
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The use of proliferation indices has, however, provided us
with a method of clarifying the varying effects of the HER4
family at a biological level. Our study shows a significant
correlation between high BLI values and HER1 positivity.
This is in keeping with previous published results [31]. It is
also consistent with other studies with the proliferation
marker Ki67 [32]. Interestingly, HER1 expression in
bladder cancer is also associated with high BrdU indices
[33]. We demonstrate a non-significant trend for HER2-
positive tumours to have a higher BLI. This is consistent
with previously published results by ourselves and others
[21,34]. However, there is evidence of a significant
correlation between Ki67 and HER2 expression [35,36].
There is no previous published evidence examining the
relationship between HER3, HER4 and BLI. However, one
study using Ki-67 showed a significant relationship
between HER3 and HER4 positivity and decreasing Ki-67
levels [19], arguing that neither of these receptors is
involved in directing proliferation. In terms of HER3 in this
study we show a non-significant trend towards higher BLI
values. In addition, when tumours positive for one or more
of HER1–3 are taken as a group they show significantly
higher proliferation rates. This is in contrast to the findings
demonstrated with Ki67 [19] but is more in keeping with
studies that have identified a poor prognostic role for
HER3 [9,16].
We demonstrate a significant inverse correlation between
HER4 positivity and BLI values. This suggests that HER4
expression in breast cancer might be involved in an anti-
proliferative role. Although a proliferative role for HER4 (in
keeping with the other HER family members) has been
suggested [37,38], there is other evidence to the contrary.
Our previous results suggest that HER4 is very rarely co-
expressed with other HER receptors [9]. Data from cell
lines have shown that activation of HER4 receptor
homodimers results in a weak biological response in
comparison with other receptor combinations [10]. Other
cell line work has shown that HER4 is necessary for
mediating the anti-proliferative and differentiation responses
elicited by neuregulin [39]. Indeed, in normal breast tissue
HER4 seems to have a critical role in the late
differentiation of mammary gland function [40]. Thus, this
evidence seems to support the association that HER4 has
with improved breast cancer survival times [9]. Some of
the conflicting evidence might be explained by the various
isoforms of HER4 [41] or by the inherent difficulty of
separating HER4 responses from those of the other family
members.
Conclusions
We have provided a biological correlate to substantiate
the deleterious effect of HER1–3 and the protective role
for HER4. This possibility of differing roles within the
HER4 family in driving proliferation has an implication in
the choice of future anti-HER treatment options. Currently
the HER2 monoclonal antibody Herceptin (trastzumab) is
being used successfully to treat patients with strongly
HER2-positive metastatic breast cancer [42]. Our results
suggest that the use of pan-HER inhibitors might not be
advised in tumours that are positive for HER4, and that
more individually directed therapies are needed.
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